The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy

Acta Urologica Japonica

Volumn 47, Issue 1, 2001, Pages 15-21

  Suzuki, Y ^a   Katoh, T ^a   Isurugi, K ^a   Obara, W ^a   Omori, S ^a   Goto, Y ^a   Fujioka, T ^a   Numasato, S ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

I PSS; Prostatic hypertrophy; Tamsulosin; Terazosin

Indexed keywords

TAMSULOSIN; TERAZOSIN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MICTURITION; MICTURITION DISORDER; PATIENT COMPLIANCE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; SULFONAMIDES; URINATION DISORDERS;

EID: 0035123564     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. α1-adrenoceptor classification: Sharpening Occam's razor
2. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications
3. Program Coordinating Committee: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
4. Guideline Subcommittee: 1999 Word Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension
5. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue
6. Naftopidil, a novel alpha 1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned alpha 1-adrenoceptor